Technology ID
TAB-2891
Novel Method and Kit Using Monoclonal Antibodies for More Sensitive Detection of Dengue Virus
E-Numbers
E-182-2014-0
Lead Inventor
Hunsperger, Elizabeth (CDC)
Co-Inventors
Taye, Tesfaye (CDC)
Poole-Smith, Betty (CDC)
Applications
Research Materials
Non-Medical Devices
Medical Devices
Diagnostics
Therapeutic Areas
Infectious Disease
Immunology
Development Stages
Prototype
Development Status
- In vitro data available
- Prototype
Research Products
Research Equipment
Antibodies
Lead IC
CDC
ICs
CDC
Following primary dengue virus (DENV) infection, non-structural protein 1 (NS1), a dengue-specific glycoprotein, is present in blood and is easily detected by various assays. However, for any infection thereafter (secondary infection), bioavailability of the glycoprotein greatly reduces sensitivity of DENV detection. Since secondary DENV infection is a risk factor for developing hemorrhagic fever, there is increasing need for more sensitive detection at this stage.
CDC investigators have developed a versatile method and monoclonal antibodies for detection of primary and secondary DENV infection. The antibodies specifically bind to heat-denatured NS1, allowing the addition of a heat denaturation step which greatly improves sensitivity of the detection assay. The assay was validated using actual dengue patient samples.
CDC investigators have developed a versatile method and monoclonal antibodies for detection of primary and secondary DENV infection. The antibodies specifically bind to heat-denatured NS1, allowing the addition of a heat denaturation step which greatly improves sensitivity of the detection assay. The assay was validated using actual dengue patient samples.
Commercial Applications
- Use of novel antibodies and methods for development of more sensitive diagnostics for primary and secondary DENV infection, including immunofluorescence assays, enzyme-linked immunosorbent assays, lateral flow assays and microsphere-based assay systems.
Competitive Advantages
- More sensitive DENV detection better for secondary infection.
- Novel antibodies and methods can be applied to existing kits to increase sensitivity and ease of use.
Licensing Contact: